Alan A Melcher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3373492/publications.pdf

Version: 2024-02-01

142	8,939	38742 50	51608 86
papers	citations	h-index	g-index

146	146	146	7396
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
2	Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Medicine, 1998, 4, 581-587.	30.7	428
3	Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nature Reviews Cancer, 2020, 20, 203-217.	28.4	420
4	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 2018, 10, .	12.4	288
5	A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clinical Cancer Research, 2008, 14, 7127-7137.	7.0	205
6	Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide. Molecular Therapy, 2011, 19, 1008-1016.	8.2	201
7	The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon. Human Gene Therapy, 2009, 20, 1119-1132.	2.7	170
8	Antiâ€“PD-1/antiâ€“CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8⁺T cell trafficking. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1540-E1549.	7.1	165
9	Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity. Journal of Immunology, 2008, 180, 6018-6026.	0.8	163
10	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Molecular Therapy, 2016, 24, 166-174.	8.2	161
11	Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity. Clinical Cancer Research, 2008, 14, 7358-7366.	7.0	157
12	Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Clinical Cancer Research, 2008, 14, 259-269.	7.0	156
13	Oncolytic viruses: a novel form of immunotherapy. Expert Review of Anticancer Therapy, 2008, 8, 1581-1588.	2.4	154
14	Measles virus causes immunogenic cell death in human melanoma. Gene Therapy, 2013, 20, 7-15.	4.5	153
15	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research, 2012, 18, 2080-2089.	7.0	151
16	Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication. Clinical Cancer Research, 2009, 15, 4374-4381.	7.0	150
17	Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy. Molecular Therapy, 2009, 17, 1667-1676.	8.2	148
18	Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. Science Translational Medicine, 2012, 4, 138ra77.	12.4	142

#	Article	IF	Citations
19	Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Therapy, 2008, 15, 911-920.	4.5	135
20	Human Tumour Immune Evasion via TGF-Î² Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity. PLoS ONE, 2011, 6, e22842.	2.5	132
21	Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature Medicine, 2008, 14, 37-44.	30.7	128
22	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research, 2010, 16, 5564-5572.	7.0	120
23	The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery. Current Cancer Drug Targets, 2010, 10, 242-267.	1.6	117
24	A simple method to cure established tumors by inflammatory killing of normal cells. Nature Biotechnology, 2004, 22, 1125-1132.	17.5	112
25	Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Therapy, 2009, 16, 689-699.	4.5	111
26	Apoptosis or necrosis for tumor immunotherapy: what's in a name?. Journal of Molecular Medicine, 1999, 77, 824-833.	3.9	102
27	Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature Biotechnology, 2012, 30, 337-343.	17.5	98
28	Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clinical Cancer Research, 2010, 16, 3067-3077.	7.0	96
29	Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer. Cancer Research, 2010, 70, 4539-4549.	0.9	94
30	Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Therapy, 2008, 15, 1257-1270.	4.5	93
31	Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy. Clinical Cancer Research, 2008, 14, 912-923.	7.0	93
32	Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine, 2011, 17, 854-859.	30.7	86
33	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 5818-5831.	7.0	86
34	Applications of coxsackievirus A21 in oncology. Oncolytic Virotherapy, 2014, 3, 47.	6.0	84
35	Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. Cancer Research, 2007, 67, 11970-11979.	0.9	83
36	Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma. Clinical Cancer Research, 2009, 15, 6158-6166.	7.0	83

#	Article	IF	Citations
37	Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of Melanocytes In vivo. Cancer Research, 2005, 65, 2009-2017.	0.9	78
38	Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus. Human Gene Therapy, 2010, 21, 439-450.	2.7	74
39	Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization. Clinical Cancer Research, 2011, 17, 2767-2776.	7.0	73
40	Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Research, 2002, 62, 5495-504.	0.9	72
41	Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. Journal of Clinical Investigation, 2010, 120, 1551-1560.	8.2	71
42	Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus. Human Gene Therapy, 2011, 22, 1343-1353.	2.7	70
43	Oncolytic virusâ€“mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Science Translational Medicine, 2022, 14, eabn2231.	12.4	70
44	Reciprocal Human Dendritic Cellâ€“Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus. Journal of Immunology, 2009, 183, 4312-4321.	0.8	69
45	Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-ÎºB mediated and supports innate and adaptive anti-tumour immune priming. Molecular Cancer, 2011, 10, 20.	19.2	64
46	Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. Clinical Cancer Research, 2009, 15, 561-569.	7.0	63
47	Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. Molecular Therapy, 2014, 22, 1851-1863.	8.2	60
48	VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling. Molecular Therapy, 2011, 19, 150-158.	8.2	59
49	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology, 2016, 18, 518-527.	1.2	57
50	Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virotherapy, 2016, 5, 1.	6.0	56
51	Cytotoxic and immuneâ€mediated killing of human colorectal cancer by reovirusâ€loaded blood and liver mononuclear cells. International Journal of Cancer, 2013, 132, 2327-2338.	5.1	53
52	Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer Immunology Research, 2018, 6, 1161-1173.	3.4	53
53	Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 2011, 11, 221.	2.6	52
54	Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature Medicine, 2013, 19, 1625-1631.	30.7	52

#	Article	IF	Citations
55	Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clinical and Experimental Immunology, 2020, 200, 33-44.	2.6	51
56	Oncolytic virotherapy as immunotherapy. Science, 2021, 374, 1325-1326.	12.6	51
57	Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 2012, 12, 368.	2.6	49
58	Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Molecular Therapy - Oncolytics, 2018, 9, 1-12.	4.4	49
59	Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, 2018, 67, 562-573.	12.1	49
60	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, 2012, 25, 1333-1344.	5.5	48
61	Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. Viruses, 2015, 7, 6291-6312.	3.3	48
62	Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Therapy, 2016, 23, 357-368.	4.5	48
63	Treg Depletionâ€“enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Molecular Therapy, 2008, 16, 1217-1226.	8.2	47
64	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications, 2020, 11, 790.	12.8	47
65	Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatinâ€“paclitaxel doublet chemotherapy. Gene Therapy, 2013, 20, 521-528.	4.5	45
66	Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer. Molecular Therapy, 2008, 16, 1910-1918.	8.2	44
67	BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Molecular Therapy, 2015, 23, 931-942.	8.2	44
68	Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. European Journal of Cancer, 2020, 131, 9-15.	2.8	44
69	Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-Î± signaling. Oncogene, 2014, 33, 1700-1712.	5.9	41
70	Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy, 2019, 27, 1139-1152.	8.2	41
71	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical Cancer Research, 2015, 21, 1305-1312.	7.0	40
72	Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas. Journal of Immunology, 2006, 177, 4168-4177.	0.8	39

#	Article	IF	Citations
73	Lymphokineâ€activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. International Journal of Cancer, 2014, 134, 1091-1101.	5.1	39
74	Recent Clinical Experience with Oncolytic Viruses. Current Pharmaceutical Biotechnology, 2012, 13, 1834-1841.	1.6	37
75	Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opinion on Biological Therapy, 2020, 20, 635-652.	3.1	36
76	Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Molecular Therapy, 2013, 21, 1507-1516.	8.2	35
77	Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy. Clinical Cancer Research, 2008, 14, 4915-4924.	7.0	34
78	Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, 2015, 29, 1799-1810.	7.2	34
79	The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice. Molecular Therapy, 2013, 21, 348-357.	8.2	33
80	Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. Molecular Therapy, 2011, 19, 140-149.	8.2	30
81	Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology, 2015, 96, 1533-1550.	2.9	30
82	Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70â€“Mediated Inflammatory Killing of Normal Pancreas. Cancer Research, 2009, 69, 7767-7774.	0.9	28
83	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British Journal of Cancer, 2012, 106, 496-507.	6.4	28
84	Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncology, 2013, 49, 108-118.	1.5	27
85	Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cellsin vivo. Clinical and Experimental Immunology, 2015, 180, 98-107.	2.6	27
86	Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. , 2019, 7, 164.		27
87	Exploiting synergies between radiation and oncolytic viruses. Current Opinion in Molecular Therapeutics, 2008, 10, 362-70.	2.8	26
88	Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy. Molecular Therapy, 2011, 19, 1802-1812.	8.2	25
89	Live viruses to treat cancer. Journal of the Royal Society of Medicine, 2013, 106, 310-314.	2.0	24
90	PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. Clinical Cancer Research, 2019, 25, 3443-3454.	7.0	24

#	Article	IF	Citations
91	Reovirus-Mediated Cytotoxicity and Enhancement of Innate Immune Responses Against Acute Myeloid Leukemia. BioResearch Open Access, 2012, 1, 3-15.	2.6	23
92	The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism. Molecular Therapy - Oncolytics, 2020, 16, 238-249.	4.4	23
93	Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors. Cancer Research, 2008, 68, 9771-9778.	0.9	22
94	Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. British Journal of Cancer, 2011, 105, 787-795.	6.4	22
95	Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opinion on Biological Therapy, 2012, 12, 1669-1678.	3.1	22
96	Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular Therapy - Oncolytics, 2017, 5, 75-86.	4.4	22
97	Subversion of NK-cell and TNFÎ± Immune Surveillance Drives Tumor Recurrence. Cancer Immunology Research, 2017, 5, 1029-1045.	3.4	22
98	RIPK1â€mediated immunogenic cell death promotes antiâ€tumour immunity against softâ€tissue sarcoma. EMBO Molecular Medicine, 2020, 12, e10979.	6.9	22
99	Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 2022, 10, 745-756.	3.4	22
100	Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Frontiers in Immunology, 2021, 12, 754436.	4.8	21
101	The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis. Molecular Therapy, 2010, 18, 2085-2093.	8.2	17
102	Definitive Management of Oligometastatic Melanoma in a Murine Model Using CombinedÂAblative Radiation Therapy andÂViralÂImmunotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 577-587.	0.8	17
103	Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors. Molecular Therapy - Oncolytics, 2021, 20, 434-446.	4.4	17
104	Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. Science Translational Medicine, 2018, 10, .	12.4	15
105	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. Journal of the National Cancer Institute, 2021, 113, 88-98.	6.3	15
106	Characterization of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2019, 37, 589-589.	1.6	15
107	The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular Therapy, 2014, 22, 1936-1948.	8.2	14
108	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy - Oncolytics, 2018, 11, 1-13.	4.4	14

#	Article	IF	Citations
109	APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable. Clinical Cancer Research, 2021, 27, 3280-3290.	7.0	14
110	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research, 2019, 7, 828-840.	3.4	13
111	Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. , 2021, 9, e001803.		12
112	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Molecular Therapy, 2015, 23, 845-856.	8.2	11
113	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. , 2020, 8, e000698.		11
114	Cancer Gene Therapy: Part 2. Candidate Transgenes and their Clinical Development. Clinical Oncology, 2002, 14, 148-169.	1.4	10
115	Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene Therapy, 2009, 16, 78-92.	4.5	9
116	Oncolytic Virotherapy: Single Cycle Cures or Repeat Treatments? (Repeat Dosing Is Crucial!). Molecular Therapy, 2018, 26, 1875-1876.	8.2	9
117	Talimogene laherparepvec in the treatment of melanoma. Expert Opinion on Biological Therapy, 2015, 15, 1517-1530.	3.1	8
118	Dendritic Cells for the Immunotherapy of Cancer. Clinical Oncology, 2002, 14, 185-192.	1.4	7
119	Viral warfare! Front-line defence and arming theÂimmune system against cancer using oncolytic vaccinia and other viruses. Journal of the Royal College of Surgeons of Edinburgh, 2014, 12, 210-220.	1.8	7
120	Synergistic antitumour effects of rapamycin and oncolytic reovirus. Cancer Gene Therapy, 2018, 25, 148-160.	4.6	7
121	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 2021, 12, 1930.	12.8	7
122	Hematopoietic stem cell gene therapy targeting TGFÎ² enhances the efficacy of irradiation therapy in a preclinical glioblastoma model. , 2021, 9, e001143.		7
123	Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances, 2022, 4, .	0.7	7
124	Cancer gene therapy: developments to 2000. Expert Opinion on Investigational Drugs, 2000, 9, 2799-2813.	4.1	6
125	Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. , 2021, 9, e002673.		5
126	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, e16016-e16016.	1.6	5

#	Article	IF	Citations
127	The Hitchhiker's Guide to Virotherapy. Oncotarget, 2012, 3, 735-736.	1.8	5
128	An Intravenous Stimulus Package for Oncolytic Virotherapy. Molecular Therapy, 2011, 19, 1930-1932.	8.2	4
129	Adenovirally Delivered Enzyme Prodrug Therapy with Herpes Simplex Virusâ€“Thymidine Kinase in Composite Tissue Free Flaps Shows Therapeutic Efficacy in Rat Models of Glioma. Plastic and Reconstructive Surgery, 2015, 135, 475-487.	1.4	4
130	Oncolytic Virus Immunotherapy. Cancers, 2021, 13, 3672.	3.7	4
131	Oncolytic virus treatment differentially affects the CD56^{dim} and CD56^{bright} NK cell subsets in vivo and regulates a spectrum of human NK cell activity. Immunology, 2022, 166, 104-120.	4.4	4
132	Immunogenicity of self tumor associated proteins is enhanced through protein truncation. Molecular Therapy - Oncolytics, 2016, 3, 16030.	4.4	3
133	Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients. Cancer Research, 2015, 75, CT205-CT205.	0.9	3
134	Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, TPS3108-TPS3108.	1.6	3
135	CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. , 2022, 10, e004410.		3
136	69. Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses. Molecular Therapy, 2015, 23, S30.	8.2	2
137	Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses. , 2015, , .		2
138	Reoviral Therapy for Cancer. , 2014, , 185-198.		1
139	Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients.. Journal of Clinical Oncology, 2014, 32, 3104-3104.	1.6	1
140	63. Immunogenicity of Self Tumor Associated Antigens Is Enhanced Through Protein Truncation. Molecular Therapy, 2016, 24, S28.	8.2	0
141	197. Balancing Anti-Tumor Efficacy with Local Inflammatory Toxicity for the Treatment of Diffuse Intrinsic Pontine Glioma and Other Brain Tumors. Molecular Therapy, 2016, 24, S77.	8.2	0
142	Abstract 4162: Lentivirally delivered shRNA knockdown of CXCL12 is effective at preventing radiation fibrosis in normal tissues. , 2018, , .		0